<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176317</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00052449</org_study_id>
    <nct_id>NCT02176317</nct_id>
  </id_info>
  <brief_title>Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)</brief_title>
  <official_title>Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Marcus Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PerkinElmer, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective phase 1 single-center trial designed to determine the safety of a&#xD;
      single intravenous infusion of autologous umbilical cord blood in children with Autism&#xD;
      Spectrum Disorder (ASD) and assess the feasibility of various outcome measures to determine&#xD;
      which measure(s) can be used as primary and secondary endpoints for a future randomized phase&#xD;
      2 clinical trial. All subjects will receive infusion of cord blood cells at baseline with&#xD;
      follow up assessments at 6 and 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autism Spectrum Disorder (ASD) is a neurodevelopment disorder with early onset in life.&#xD;
      Currently, available treatments for patients with ASD are supportive, but not curative.&#xD;
      Umbilical cord blood (UCB) has been shown to lessen the clinical and radiographic impact of&#xD;
      hypoxic brain injury and stroke in animal models and in infants with hypoxic ischemic&#xD;
      encephalopathy. UCB also engrafts and differentiates in the brain, facilitating neural cell&#xD;
      repair in animal models and human patients with inborn errors of metabolism undergoing&#xD;
      allogeneic, unrelated donor UCB transplantation. Infusion of autologous UCB does not require&#xD;
      immunosuppression and has been shown to be safe in young children with brain injuries such as&#xD;
      cerebral palsy and stroke. In this study, the investigators hypothesize that infusion of a&#xD;
      patient's own umbilical cord blood cells (UCB) can offer neural protection/repair in the&#xD;
      brain and reduction of inflammation associated with this disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with non-serious and serious adverse events.</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The primary efficacy measure will be change in the Vineland Adaptive Behavior Scale- II</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Pervasive Developmental Disorder- Behavior Inventory</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Repetitive Behavior Scal</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Sensory Experience Questionnaire</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Behavior Assessment of Children</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Autism Diagnostic Observation Scale</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Clinical Global Impression- Severity and Improvement Scales</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Stanford Binet Intelligence Scale or other standardized IQ test</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in frequency of child vocalization/ conversational turns</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Expressive One-Word Picture Vocabulary Test</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Preschool Age Psychiatric Assessment</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Aberrant Behavior Checklist</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prevalent and incident of GI symptoms</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Parenting Stress Index</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in attention to social stimuli assessed via eye-tracking and electroencephalography (EEG)</measure>
    <time_frame>up to 12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Autologous Umbilical Cord Blood (UCB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Umbilical Cord Blood</intervention_name>
    <description>All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes</description>
    <arm_group_label>Autologous Umbilical Cord Blood (UCB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 24 months to ≤72months at the time of visit 1&#xD;
&#xD;
          2. Confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using all three of the&#xD;
             following measures:&#xD;
&#xD;
               -  Autism Diagnostic Observation Schedule - Toddler or Generic (ADOS)&#xD;
&#xD;
               -  Autism Diagnostic Interview-Revised (ADI-R)&#xD;
&#xD;
               -  DSM-5 checklist&#xD;
&#xD;
          3. IQ ≥ 35 on Stanford Binet Intelligence Scale or similar standardized test&#xD;
&#xD;
          4. Autologous umbilical cord blood available from a cord blood bank with a minimum total&#xD;
             nucleated cell dose of ≥ 1 x 107 cells/kilogram of subject weight that meets&#xD;
             acceptance criteria outlined in section 6.0 with confirmed HLA matching&#xD;
&#xD;
          5. Stable on current medications for at least 2 months prior to infusion of cord blood&#xD;
&#xD;
          6. Ability to travel to Duke University three times (0, 6, 12 mo.), parent/guardian able&#xD;
             to participate in electronic communication tracking two times in the study and interim&#xD;
             phone surveys every 3 months&#xD;
&#xD;
          7. Parental consent&#xD;
&#xD;
          8. Subject and parent/guardian must be English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling to commit to follow up for a year&#xD;
&#xD;
          2. History of prior cell therapy&#xD;
&#xD;
          3. Use of IVIG or other anti-inflammatory medications with the exception of NSAIDs&#xD;
&#xD;
          4. Medical records indicate that child has genetic or other syndromes such as fragile X,&#xD;
             neurofibromatosis, Rett syndrome, tuberous sclerosis, PTEN mutation, cerebral palsy,&#xD;
             cystic fibrosis, muscular dystrophy, Crohn's disease, or rheumatoid disease&#xD;
&#xD;
          5. Co-morbid condition that would influence child's performance on assessments.&#xD;
&#xD;
          6. Central Nervous System (CNS) infection&#xD;
&#xD;
          7. History of unstable epilepsy or uncontrolled seizure disorder, infantile spasms,&#xD;
             Lennox Gastaut syndrome, Dravet syndrome&#xD;
&#xD;
          8. Known pathogenic copy number variation (CNV) (e.g. 16p11.2, 15q13.2, 2q13.3)&#xD;
&#xD;
          9. Significant sensory (i.e., deafness, blind) or motor impairment (CP) (if using&#xD;
             Language Environment Analysis (LENA), no uncorrected hearing impairment)&#xD;
&#xD;
         10. Presence of obvious physical dysmorphology&#xD;
&#xD;
         11. Review of medical records indicates ASD diagnosis not likely or other serious&#xD;
             complicating genetic or medical condition present&#xD;
&#xD;
         12. Impaired renal or liver function as determined by serum creatinine &gt;1.5mg/dL and/or&#xD;
             total bilirubin&gt;1.3mg/dL&#xD;
&#xD;
         13. Clinically significant abnormalities in Complete Blood Count (CBC): Hemoglobin &lt; 10.0&#xD;
             g/dL, White Blood Count (WBC) &lt; 3.8 x 10e9, Platelets &lt; 150x 10e9.&#xD;
&#xD;
         14. Known metabolic disorder, mitochondrial dysfunction&#xD;
&#xD;
         15. Uncontrolled infection, presence of or infection with HIV&#xD;
&#xD;
         16. Active malignancy&#xD;
&#xD;
         17. Macroencephaly or microencephaly ( &gt;2 standard deviations in the relevant direction&#xD;
             between head circumference and height)&#xD;
&#xD;
         18. Change in current stable use of psychoactive medications; as per parent report.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>72 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Kurtzberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Joanne Kurtzberg, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>ASD</keyword>
  <keyword>Umbilical cord blood</keyword>
  <keyword>Autologous cord blood</keyword>
  <keyword>cord blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

